glp·helper
glphelper.com/mounjaro/california/roseville
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022Rx · Subcutaneous injection · Once weekly

Mounjaro® providers &
prescriptions in Roseville, CA

Verified Mounjaro providers in Roseville, CA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Mounjaro weight loss →trial-anchored estimate
city providers
39
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: California
40 of 40 shown

Find a Mounjaro provider in California.

Every entry is checked against the NPI registry and the California medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by California city · /mounjaro/california/{city}
§ 03Getting Mounjaro in Roseville
40 providers · Roseville, CA

How to get Mounjaro in Roseville.

40 GLP-1 prescribers and 7 local resource types are on record for Roseville, plus 3 nearby towns in the directory.

Prescribers in Roseville
40 prescribers
40 GLP-1 prescribers in Roseville, most listed as Internal Medicine, Endocrinology, Diabetes & Metabolism (14), Family Medicine (12) and Internal Medicine (9). Any California-licensed physician, nurse practitioner, or PA can prescribe Mounjaro, over video or in person. The nearest towns on record are Rocklin (33 providers), Citrus Heights (30 providers) and Lincoln (28 providers).
Around the prescription in Roseville
7 listed nearby
67 dietitians, 10 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Roseville.
Medicaid (weight loss)
Diabetes only
As of April 2026, California Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm California’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes. Same molecule as Zepbound.

Mounjaro is the brand name Eli Lilly uses for tirzepatide approved for type 2 diabetes. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one. The identical molecule, marketed as Zepbound, is the FDA-approved formulation for chronic weight management.[2][3]

In the SURPASS-2 head-to-head trial, tirzepatide produced greater HbA1c reductions and greater weight loss than semaglutide 1 mg across all doses. Across the SURPASS program, tirzepatide lowered HbA1c by approximately 1.8 to 2.6 percentage points. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.[1]

At a glanceMultiple (per dose)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Weight management (Zepbound is the FDA-approved tirzepatide for obesity)
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Roseville

Roseville, California has a population of 147,773 people. The adult obesity rate in Roseville is an age-adjusted estimate of 27%, 2.1 percentage points below the California state rate of 29.1%. Diagnosed diabetes reaches 8% of adults in Roseville. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 18.2% of adults in Roseville.

of Roseville adults have obesity
27%
diagnosed diabetes
8%
no regular physical activity
18.2%

Age-adjusted estimates for Roseville, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossGLP-1s during menopause
§ 05Support around Mounjaro in Roseville
6 nutritionists

The prescription is one part. Here is the rest, in Roseville.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Roseville, CA, ordered as the registry lists them, never by who pays us.

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Katie Callahan
NUTRITIONIST
Nutritionist
572 Gibson Dr Apt 1714
Call 916-542-3962NPI 1033051453
Paula Clayton, CN
NUTRITIONIST
Nutritionist
1431 Spring Valley Dr
Call 916-676-5197NPI 1477037927
Pamela Connor, clinical nutritionis
NUTRITIONIST
Nutritionist
1891 E Roseville Pkwy Ste 170
Call 916-404-0886NPI 1730987785
Cynthia Fairman, RD CDE
NUTRITIONIST
Nutritionist
6555 Coyle Ave
Call 916-536-3540NPI 1235268269
Nathalie Patino
NUTRITIONIST
Nutritionist · Education
301 Gibson Dr Apt 726
Call 916-217-2130NPI 1720832116
Paulette Perfumo, PhD
NUTRITIONIST
Nutritionist
413 Hearthstone Ct
Call 707-580-1589NPI 1487012712

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

InstaPhysique (Roseville)
FITNESS
5.0 on Google · 162 reviews
1470 Eureka Rd #100
Website
Mahany Fitness Center
FITNESS
4.5 on Google · 157 reviews
1545 Pleasant Grove Blvd
Website
Positive Impact Fitness
FITNESS
5.0 on Google · 18 reviews
1040 Pleasant Grove Blvd #130
Website
24 Hour Fitness
GYM
4.4 on Google · 1426 reviews
1533 Blue Oaks Blvd
Website
Life Time
GYM
4.1 on Google · 538 reviews
1435 E Roseville Pkwy
Website
In-Shape Fitness
GYM
4.4 on Google · 384 reviews
5001 Foothills Blvd
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

Across the SURPASS program, tirzepatide reduced HbA1c by approximately 1.8 to 2.6 percentage points and produced substantial weight loss, outperforming insulin and GLP-1 comparators. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with T2D.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Mean weight change (15 mg, obesity)
−20.9%
SURMOUNT-1, 72 wk (Zepbound)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Mounjaro weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Mounjaro cash price (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Mounjaro providers in California

NPI-verified Mounjaro (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Mounjaro in other states

Find NPI-verified Mounjaro (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Mounjaro in California

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Mounjaro and Zepbound are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Insurers treat them as separate products, and coverage differs sharply between the two.[1]